Programs

Pipeline

One molecule. Three indication tracks. Stage indicators reflect Tethra's current and planned development.

Program
Indication
Stage
Status
Phase 1/2 trial · same protocol covers both indications Trial 1 · Active
Plogosertib PLK1 + BRD4 inhibitor · Tethra Bio
Solid tumors biomarker-defined
DiscoveryPreclin.INDPhase 1Phase 2
Active P1/2
Plogosertib PLK1-sensitive · Tethra Bio
Lymphoma biomarker-defined
DiscoveryPreclin.INDPhase 1Phase 2
Active P1/2
Plogosertib + Combination Combination · Tethra Bio
AML biomarker-defined
DiscoveryPreclin.INDPhase 1Phase 2
Planned 2027
Open plogosertib detail →

Status notes

What's next

Solid tumors · Active P1/2

plogosertib (THT-140) is in active Phase 1/2 development in biomarker-defined solid tumors.

Lymphoma · Active P1/2

plogosertib (THT-140) is in active Phase 1/2 development in lymphoma, under the same protocol as the solid-tumor cohort.

AML · Planned 2027

plogosertib combination program in mutation-defined AML; IND-stage development with trial start planned for 2027.

Active trial details and ClinicalTrials.gov identifiers will be posted as records are updated.

plogosertib (THT-140) is investigational and has not been approved by any health authority. Stage indicators reflect Tethra's planned development trajectory and are subject to regulatory clearance and trial outcomes.